Identification

Name
Zomepirac
Accession Number
DB04828
Type
Small Molecule
Groups
Withdrawn
Description

Zomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions. The manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.

Structure
Thumb
Synonyms
  • 5-(4-Chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-2-acetic acid
  • Zomepiracum
Product Ingredients
IngredientUNIICASInChI Key
Zomepirac sodiumDA5B6IWF4664092-48-4SEEXPXUCHVGZGU-UHFFFAOYSA-M
Zomepirac sodium dihydrateY0185WZ20964092-49-5Not applicable
Categories
UNII
822G987U9J
CAS number
33369-31-2
Weight
Average: 291.73
Monoisotopic: 291.066221026
Chemical Formula
C15H14ClNO3
InChI Key
ZXVNMYWKKDOREA-UHFFFAOYSA-N
InChI
InChI=1S/C15H14ClNO3/c1-9-7-12(8-13(18)19)17(2)14(9)15(20)10-3-5-11(16)6-4-10/h3-7H,8H2,1-2H3,(H,18,19)
IUPAC Name
2-[5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrol-2-yl]acetic acid
SMILES
CN1C(CC(O)=O)=CC(C)=C1C(=O)C1=CC=C(Cl)C=C1

Pharmacology

Indication

Zomepirac was indicated for the management of mild to severe pain.

Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UProstaglandin D2 receptor 2Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when Zomepirac is combined with (4R)-limonene.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Zomepirac is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Zomepirac is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Zomepirac is combined with 5-androstenedione.Experimental, Illicit
AbciximabZomepirac may increase the anticoagulant activities of Abciximab.Approved
AcebutololZomepirac may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolZomepirac may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Acetaminophen.Approved
Acetyl sulfisoxazoleThe metabolism of Zomepirac can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Zomepirac.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Alendronic acid.Approved
AliskirenZomepirac may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Alminoprofen.Experimental
AlprenololZomepirac may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Zomepirac.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Amcinonide.Approved
AmikacinZomepirac may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideZomepirac may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Zomepirac can be decreased when combined with Amiodarone.Approved, Investigational
AncrodZomepirac may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Zomepirac is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Zomepirac is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Zomepirac is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Zomepirac is combined with Antipyrine.Approved, Investigational
Antithrombin III humanZomepirac may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Zomepirac is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Zomepirac can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanZomepirac may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Zomepirac is combined with Apocynin.Investigational
ApramycinZomepirac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Zomepirac is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Zomepirac can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinZomepirac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinZomepirac may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanZomepirac may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololZomepirac may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineZomepirac may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Atamestane.Investigational
AtazanavirThe metabolism of Zomepirac can be decreased when combined with Atazanavir.Approved, Investigational
AtenololZomepirac may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Zomepirac can be decreased when combined with Atomoxetine.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Zomepirac.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Zomepirac is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Zomepirac.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Zomepirac.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Balsalazide.Approved, Investigational
BecaplerminZomepirac may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololZomepirac may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinZomepirac may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Zomepirac.Approved
BenorilateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Zomepirac.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Zomepirac.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Zomepirac is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Zomepirac.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Betamethasone.Approved, Vet Approved
BetaxololZomepirac may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Zomepirac.Approved, Investigational
BevantololZomepirac may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Zomepirac is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Zomepirac.Approved, Investigational
BisoprololZomepirac may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinZomepirac may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Zomepirac can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololZomepirac may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Zomepirac can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Zomepirac can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Zomepirac is combined with Bucillamine.Investigational
BucindololZomepirac may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Bufexamac.Approved, Experimental
BufuralolZomepirac may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Zomepirac.Approved
BupranololZomepirac may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Zomepirac.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Zomepirac.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Captopril.Approved
CarbamazepineThe metabolism of Zomepirac can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Zomepirac is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Zomepirac.Approved
CarprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololZomepirac may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolZomepirac may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Zomepirac.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Zomepirac is combined with Celecoxib.Approved, Investigational
CeliprololZomepirac may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Zomepirac can be increased when it is combined with Ceritinib.Approved
CertoparinZomepirac may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Zomepirac.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zomepirac.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Zomepirac.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Zomepirac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Zomepirac is combined with Cimicoxib.Investigational
CinoxacinZomepirac may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinZomepirac may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Cisplatin.Approved
Citric AcidZomepirac may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Zomepirac can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Zomepirac can be decreased when combined with Clemastine.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Zomepirac.Vet Approved
CloranololZomepirac may decrease the antihypertensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Zomepirac can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Zomepirac can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Zomepirac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Zomepirac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Zomepirac.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Cortisone acetate.Approved, Investigational
CrizotinibThe metabolism of Zomepirac can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Zomepirac can be decreased when combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Zomepirac.Experimental
CyclosporineZomepirac may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateZomepirac may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Zomepirac can be decreased when it is combined with Dabrafenib.Approved, Investigational
DalteparinZomepirac may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidZomepirac may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanZomepirac may increase the anticoagulant activities of Darexaban.Investigational
DarunavirThe metabolism of Zomepirac can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Zomepirac can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Zomepirac can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Zomepirac is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Delapril.Investigational
DelavirdineThe metabolism of Zomepirac can be decreased when combined with Delavirdine.Approved
DesipramineZomepirac may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinZomepirac may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Zomepirac.Approved, Investigational
DextranZomepirac may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinZomepirac may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Zomepirac is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Zomepirac.Approved, Vet Approved
DicoumarolZomepirac may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Zomepirac is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Zomepirac.Approved
DihydroergotamineThe metabolism of Zomepirac can be decreased when combined with Dihydroergotamine.Approved, Investigational
DihydrostreptomycinZomepirac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe metabolism of Zomepirac can be decreased when combined with Diltiazem.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Zomepirac.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Zomepirac.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Zomepirac.Approved
DoxycyclineThe metabolism of Zomepirac can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Zomepirac can be decreased when combined with Dronedarone.Approved
DrospirenoneZomepirac may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Zomepirac is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Zomepirac is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Zomepirac is combined with E-6201.Investigational
Edetic AcidZomepirac may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanZomepirac may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Zomepirac is combined with Enalaprilat.Approved
EnoxacinZomepirac may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinZomepirac may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Zomepirac.Experimental
EnzalutamideThe serum concentration of Zomepirac can be decreased when it is combined with Enzalutamide.Approved
EpanololZomepirac may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Zomepirac is combined with Epirizole.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Zomepirac.Experimental
EplerenoneZomepirac may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Zomepirac.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Zomepirac.Approved
EquileninThe risk or severity of adverse effects can be increased when Zomepirac is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Equilin.Approved
ErythromycinThe metabolism of Zomepirac can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololZomepirac may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololZomepirac may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Zomepirac.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Zomepirac is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ethenzamide.Experimental
Ethyl biscoumacetateZomepirac may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Zomepirac is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Evening primrose oil.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Zomepirac is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Zomepirac.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Feprazone.Experimental
Ferulic acidZomepirac may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Zomepirac.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fish oil.Approved, Nutraceutical
FleroxacinZomepirac may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Zomepirac.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluasterone.Investigational
FluconazoleThe metabolism of Zomepirac can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fludrocortisone.Approved, Investigational
FluindioneZomepirac may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineZomepirac may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Zomepirac.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Zomepirac can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Zomepirac.Approved, Nutraceutical, Vet Approved
FondaparinuxZomepirac may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Zomepirac.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Zomepirac can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Zomepirac can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Zomepirac can be increased when combined with Fosphenytoin.Approved, Investigational
FramycetinZomepirac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Zomepirac.Approved, Vet Approved
Fusidic AcidThe serum concentration of Zomepirac can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabexateZomepirac may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinZomepirac may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinZomepirac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Zomepirac.Approved, Withdrawn
GemifloxacinZomepirac may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinZomepirac may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinZomepirac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AZomepirac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinZomepirac may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Zomepirac is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Zomepirac is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Zomepirac is combined with HE3286.Investigational
HeparinZomepirac may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Zomepirac is combined with Higenamine.Investigational
HydralazineZomepirac may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Zomepirac.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Zomepirac.Approved, Investigational
Hygromycin BZomepirac may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Zomepirac is combined with Icatibant.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Zomepirac is combined with Icosapent.Approved, Nutraceutical
IdelalisibThe metabolism of Zomepirac can be decreased when combined with Idelalisib.Approved
IdraparinuxZomepirac may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Zomepirac.Approved, Investigational
ImatinibThe metabolism of Zomepirac can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Zomepirac.Approved
IndenololZomepirac may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Zomepirac can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Indoprofen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Zomepirac.Approved, Investigational
IsavuconazoleThe serum concentration of Zomepirac can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Zomepirac can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinZomepirac may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Zomepirac is combined with Isoxicam.Withdrawn
IsradipineThe metabolism of Zomepirac can be decreased when combined with Isradipine.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Zomepirac is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Zomepirac can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Zomepirac can be increased when it is combined with Ivacaftor.Approved
KanamycinZomepirac may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Zomepirac can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Zomepirac.Approved
LabetalolZomepirac may decrease the antihypertensive activities of Labetalol.Approved
LandiololZomepirac may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Zomepirac.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Zomepirac.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Zomepirac.Approved, Investigational
LepirudinZomepirac may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanZomepirac may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololZomepirac may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololZomepirac may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinZomepirac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Zomepirac.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Zomepirac is combined with Lisofylline.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Zomepirac.Experimental
LomefloxacinZomepirac may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Lonazolac.Experimental
LopinavirThe metabolism of Zomepirac can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Zomepirac is combined with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Zomepirac can be increased when it is combined with Lorpiprazole.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Zomepirac.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Zomepirac is combined with Loteprednol.Approved
LovastatinThe metabolism of Zomepirac can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Zomepirac.Approved, Investigational
LuliconazoleThe serum concentration of Zomepirac can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Zomepirac can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Zomepirac is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Zomepirac.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Zomepirac.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Zomepirac is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Mefenamic acid.Approved
MelagatranZomepirac may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Zomepirac is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Zomepirac is combined with Meloxicam.Approved, Vet Approved
MepindololZomepirac may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Zomepirac is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Zomepirac.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Zomepirac.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zomepirac.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Methylprednisolone.Approved, Vet Approved
MetipranololZomepirac may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Zomepirac.Approved
MetoprololZomepirac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MicronomicinZomepirac may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Zomepirac.Approved, Experimental
MifepristoneThe serum concentration of Zomepirac can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Zomepirac.Approved
MitotaneThe serum concentration of Zomepirac can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Zomepirac is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Zomepirac.Approved
MoxifloxacinZomepirac may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zomepirac.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zomepirac.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Nabumetone.Approved
NadololZomepirac may decrease the antihypertensive activities of Nadolol.Approved
NadroparinZomepirac may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatZomepirac may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Zomepirac.Approved
Nalidixic AcidZomepirac may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Zomepirac is combined with NCX 1022.Investigational
NeamineZomepirac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololZomepirac may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Zomepirac can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Zomepirac can be decreased when combined with Nelfinavir.Approved
NemonoxacinZomepirac may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinZomepirac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Nepafenac.Approved, Investigational
NetilmicinZomepirac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NetupitantThe serum concentration of Zomepirac can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Zomepirac can be increased when combined with Nevirapine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Niflumic Acid.Approved
NilotinibThe metabolism of Zomepirac can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Nitroaspirin.Investigational
NorfloxacinZomepirac may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinZomepirac may increase the neuroexcitatory activities of Ofloxacin.Approved
OlaparibThe metabolism of Zomepirac can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Zomepirac.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zomepirac.Approved
OlsalazineZomepirac may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Zomepirac is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Zomepirac is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Zomepirac can be increased when it is combined with Osimertinib.Approved
OtamixabanZomepirac may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Oxaprozin.Approved
Oxolinic acidZomepirac may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololZomepirac may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zomepirac.Approved, Withdrawn
PalbociclibThe serum concentration of Zomepirac can be increased when it is combined with Palbociclib.Approved, Investigational
PalmidrolThe risk or severity of adverse effects can be increased when Zomepirac is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Zomepirac is combined with Parecoxib.Approved
ParomomycinZomepirac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Parthenolide.Approved, Investigational
PazufloxacinZomepirac may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinZomepirac may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololZomepirac may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateZomepirac may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentobarbitalThe metabolism of Zomepirac can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
Pentosan PolysulfateZomepirac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Perindopril.Approved
PhenindioneZomepirac may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Zomepirac can be increased when combined with Phenobarbital.Approved, Investigational
PhenprocoumonZomepirac may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Zomepirac can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zomepirac.Approved, Investigational
PindololZomepirac may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidZomepirac may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Zomepirac.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pirfenidone.Approved, Investigational
Piromidic acidZomepirac may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Zomepirac is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pirprofen.Experimental
PitolisantThe serum concentration of Zomepirac can be decreased when it is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorZomepirac may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinZomepirac may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Zomepirac.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Zomepirac can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium CitrateZomepirac may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololZomepirac may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Zomepirac.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pregnenolone.Approved, Experimental, Investigational
PrimidoneThe metabolism of Zomepirac can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Zomepirac can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Zomepirac is combined with Propacetamol.Approved, Investigational
PropafenoneZomepirac may decrease the antihypertensive activities of Propafenone.Approved
PropranololZomepirac may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Zomepirac.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Zomepirac.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Zomepirac.Vet Approved
Protein CZomepirac may increase the anticoagulant activities of Protein C.Approved
Protein S humanZomepirac may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeZomepirac may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinZomepirac may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Zomepirac is combined with PTC299.Investigational
PuromycinZomepirac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Zomepirac.Approved
RamiprilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ramipril.Approved
RanolazineThe metabolism of Zomepirac can be decreased when combined with Ranolazine.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Zomepirac is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Zomepirac is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinZomepirac may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinZomepirac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifabutinThe metabolism of Zomepirac can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Zomepirac can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Zomepirac can be increased when combined with Rifapentine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Risedronate.Approved, Investigational
RivaroxabanZomepirac may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Zomepirac is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinZomepirac may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RucaparibThe metabolism of Zomepirac can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinZomepirac may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Zomepirac.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Zomepirac.Experimental
SaquinavirThe metabolism of Zomepirac can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Zomepirac.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Zomepirac.Approved, Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Zomepirac is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Zomepirac is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Zomepirac is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Zomepirac is combined with Serrapeptase.Investigational
SildenafilThe metabolism of Zomepirac can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Zomepirac can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Zomepirac can be increased when it is combined with Simeprevir.Approved
SisomicinZomepirac may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinZomepirac may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateZomepirac may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicSodium phosphate may increase the nephrotoxic activities of Zomepirac.Approved
SotalolZomepirac may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinZomepirac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Spirapril.Approved
SpironolactoneZomepirac may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Zomepirac is combined with SRT501.Investigational
St. John's WortThe serum concentration of Zomepirac can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Zomepirac can be increased when it is combined with Stiripentol.Approved
StreptomycinZomepirac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Zomepirac is combined with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Zomepirac can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Sulindac.Approved, Investigational
SulodexideZomepirac may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Zomepirac.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Suxibuzone.Experimental
TacrolimusZomepirac may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Zomepirac.Approved
TalinololZomepirac may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Zomepirac.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Zomepirac.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Technetium Tc-99m medronate.Approved
TelaprevirThe metabolism of Zomepirac can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Zomepirac can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Zomepirac.Approved, Investigational
TemafloxacinZomepirac may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tepoxalin.Vet Approved
TerbutalineZomepirac may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Teriflunomide.Approved
TertatololZomepirac may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tiaprofenic acid.Approved
TiclopidineThe metabolism of Zomepirac can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololZomepirac may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tixocortol.Approved, Withdrawn
TobramycinZomepirac may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Zomepirac can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Zomepirac.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Zomepirac.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Zomepirac.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Triamcinolone.Approved, Vet Approved
TriamtereneZomepirac may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Zomepirac.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Triptolide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Trolamine salicylate.Approved
TrovafloxacinZomepirac may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinZomepirac may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Zomepirac.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Zomepirac is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Zomepirac.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Zomepirac.Approved
VemurafenibThe serum concentration of Zomepirac can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Zomepirac can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Zomepirac can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Zomepirac can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinZomepirac may increase the anticoagulant activities of Warfarin.Approved
XimelagatranZomepirac may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Zomepirac.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Zomepirac can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Zoledronic acid.Approved
Food Interactions
Not Available

References

Synthesis Reference

James B. Doherty, Debra L. Allison, "Process for the preparation of zomepirac and related compounds." U.S. Patent US4374997, issued January, 1978.

US4374997
General References
Not Available
External Links
PubChem Compound
5733
PubChem Substance
46504549
ChemSpider
5531
BindingDB
50027952
ChEBI
35859
ChEMBL
CHEMBL19490
PharmGKB
PA166049188
HET
ZOM
Wikipedia
Zomepirac
ATC Codes
M01AB04 — Zomepirac
PDB Entries
3r8h / 4jq3

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)178.5 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.026 mg/mLALOGPS
logP3.37ALOGPS
logP3.33ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.86ChemAxon
pKa (Strongest Basic)-7.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59.3 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity77.2 m3·mol-1ChemAxon
Polarizability29.68 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9714
Blood Brain Barrier+0.8608
Caco-2 permeable+0.7695
P-glycoprotein substrateNon-substrate0.7316
P-glycoprotein inhibitor INon-inhibitor0.9347
P-glycoprotein inhibitor IINon-inhibitor0.9287
Renal organic cation transporterNon-inhibitor0.7965
CYP450 2C9 substrateNon-substrate0.7288
CYP450 2D6 substrateNon-substrate0.8163
CYP450 3A4 substrateNon-substrate0.5337
CYP450 1A2 substrateNon-inhibitor0.7776
CYP450 2C9 inhibitorNon-inhibitor0.8844
CYP450 2D6 inhibitorNon-inhibitor0.8955
CYP450 2C19 inhibitorNon-inhibitor0.7741
CYP450 3A4 inhibitorNon-inhibitor0.8973
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8525
Ames testNon AMES toxic0.8817
CarcinogenicityNon-carcinogens0.8425
BiodegradationNot ready biodegradable0.9476
Rat acute toxicity2.7638 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9389
hERG inhibition (predictor II)Non-inhibitor0.8816
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aryl-phenylketones. These are aromatic compounds containing a ketone substituted by one aryl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Aryl-phenylketones
Alternative Parents
Benzoyl derivatives / Chlorobenzenes / N-methylpyrroles / Aryl chlorides / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 3 more
Substituents
Aryl-phenylketone / Benzoyl / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Substituted pyrrole / N-methylpyrrole
show 15 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monocarboxylic acid, monochlorobenzenes, aromatic ketone, pyrroles (CHEBI:35859)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Prostaglandin j receptor activity
Specific Function
Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-protein. Receptor activation may result in pertussis toxin-sensitive decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is al...
Gene Name
PTGDR2
Uniprot ID
Q9Y5Y4
Uniprot Name
Prostaglandin D2 receptor 2
Molecular Weight
43267.15 Da
References
  1. Hata AN, Lybrand TP, Marnett LJ, Breyer RM: Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2. Mol Pharmacol. 2005 Mar;67(3):640-7. Epub 2004 Nov 24. [PubMed:15563582]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Pritchard JF, O'Neill PJ, Affrime MB, Lowenthal DT: Influence of uremia, hemodialysis, and nonesterified fatty acids on zomepirac plasma protein binding. Clin Pharmacol Ther. 1983 Nov;34(5):681-8. [PubMed:6627828]
  2. Ojingwa JC, Spahn-Langguth H, Benet LZ: Reversible binding of tolmetin, zomepirac, and their glucuronide conjugates to human serum albumin and plasma. J Pharmacokinet Biopharm. 1994 Feb;22(1):19-40. [PubMed:8027947]

Drug created on September 11, 2007 14:33 / Updated on July 18, 2018 19:42